Evidence map›Paper›PMID 39835823›Full record

ArticleJournal of clinical microbiology2025

Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease.

Hanne Lamberink, Sammy Huygens, Robina Aerts, Katrien Lagrou, Karin van Dijk, Diana Langerak, Ine Moors, Jerina Boelens, Marijke Reynders, Johan Maertens and 6 more

Erratum issuedAbstract readMulticenter StudyValidation StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Hanne LamberinkDepartment of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-2304-1353
Sammy HuygensDepartment of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-9418-8256
Robina AertsDepartment of Hematology, Leuven University Hospitals, Leuven, Belgium.ORCID 0000-0001-6337-6636
Katrien LagrouDepartment of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.ORCID 0000-0001-8668-1350
Karin van DijkDepartment of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Amsterdam, the Netherlands.ORCID 0000-0002-2054-2857
Diana LangerakDepartment of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.
Ine MoorsDepartment of Hematology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0003-3079-8909
Jerina BoelensDepartment of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0003-2282-8194
Marijke ReyndersDepartment of Laboratory Medicine, Sint-Jan Brugge-Oostende General Hospital, Bruges, Belgium.ORCID 0000-0003-2079-1279
Johan MaertensDepartment of Hematology, Leuven University Hospitals, Leuven, Belgium.ORCID 0000-0003-4257-5980
Alexander SchauwvliegheDepartment of Hematology, Sint-Jan Brugge-Oostende General Hospital, Bruges, Belgium.ORCID 0000-0002-3224-3969
Mireille van WestreenenDepartment of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-7705-7342
Ga-Lai M ChongDepartment of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-6535-2213
Paul E VerweijDepartment of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID 0000-0002-8600-9860
Jochem B BuilDepartment of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID 0000-0003-4031-0778
Bart J A RijndersDepartment of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0003-3343-9610

Funding

Selinion B.V.
6 · The paper itself

Abstract

An accurate diagnosis of invasive aspergillosis (IA) in patients with underlying hematological malignancies relies heavily on galactomannan detection. In this study, we compared the VirCLIA chemiluminescence immunoassay (CLIA) with the frequently used Platelia enzyme-linked immunosorbent assay (ELISA) on serum from hematology patients with suspected IA. Patients were categorized according to EORTC/MSGERC 2020 definitions into proven/probable IA and possible/no IA. The first cohort included 161 patients at four centers, and the VirCLIA manufacturer's cutoff of 0.200 was evaluated. Next, the optimal cutoff was determined using the Youden's index. In a second independent cohort of 189 patients from four centers, this optimal cutoff was evaluated again. In the first cohort, sensitivities and specificities for probable/proven IA were 21.1% and 100.0% for ELISA (1.0 cutoff) and 36.6% and 95.6% (0.5 cutoff), compared to 11.3% and 97.8% for CLIA (0.200 cutoff). In the second cohort, the sensitivities of ELISA and CLIA were comparable (ELISA ≥ 1.0: 33.3%, CLIA ≥ 0.200: 38.1%). The area under the ROC curve was lower for CLIA than for ELISA in the first cohort (65.0% vs 78.7%,

Indexed as

Hematologic DiseasesInvasive Pulmonary AspergillosisLuminescent MeasurementsMannansPulmonary AspergillosisAdultAgedAged, 80 and overEnzyme-Linked Immunosorbent AssayFemaleGalactoseHematologic NeoplasmsHumansImmunoassayMaleMiddle AgedgalactomannanGalactoseMannanschemiluminescence assaygalactomannaninvasive aspergillosis

Identifiers

PMID39835823
PMCPMC11837514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.